Dr. Reddy's Laboratories is currently trading at Rs. 5243.10, up by 11.45 points or 0.22% from its previous closing of Rs. 5231.65 on the BSE.
The scrip opened at Rs. 5248.95 and has touched a high and low of Rs. 5272.35 and Rs. 5042.65 respectively. So far 3880 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,272.35 on 06-Jul-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022.
Last one week high and low of the scrip stood at Rs. 5272.35 and Rs. 5042.65 respectively. The current market cap of the company is Rs. 87323.38 crore.
The promoters holding in the company stood at 26.70%, while Institutions and Non-Institutions held 50.30% and 11.70% respectively.
Dr Reddy’s Laboratories has forayed into child nutrition space by launching CeleHealth Kidz Immuno Plus Gummies in India. The immunity supporting gummies are fortified by scientifically formulated combination of ingredients such as Wellmune, prebiotics and other essential vitamins and minerals.
Wellmune is a form of clinically studied beta-glucan and a proven ingredient to help reduce sick days in children by enhancing their innate immunity. Dr Reddy’s CeleHealth Kidz Immuno Plus Gummies aim to address the nutritional requirements due to the growing issues around child immunity in India.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: